JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB286279

Human RET knockout MCF7 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

RET KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.

View Alternative Names

C ret, CDHF 12, CDHR16, Cadherin family member 12, Cadherin related family member 16, ELKS Fusion gene, HSCR 1, MEN2A, MEN2B, MTC 1, Multiple endocrine neoplasia and medullary thyroid carcinoma 1, Oncogene RET, PTC, Proto-oncogene c-Ret, Proto-oncogene tyrosine-protein kinase receptor ret, RET ELE1, RET transforming sequence, RET51, RET9, RET_HUMAN, Ret Proto oncogene, hydroxyaryl-protein kinase, tyrosine-protein kinase receptor ret

1 Images
Next Generation Sequencing - Human RET knockout MCF7 cell line (AB286279)
  • NGS

Lab

Next Generation Sequencing - Human RET knockout MCF7 cell line (AB286279)

104 bp deletion (allele 1) and 37 bp deletion in exon 4, CCDS7200.1

Key facts

Cell type

MCF7

Species or organism

Human

Tissue

Breast

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Recommended control: Human wild-type MCF7 cell line (ab288560). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Properties and storage information

Gene name
RET
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • Slow to trypsinise.
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 5-7x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

MEM + 10% FBS + 0.01 mg/ml bovine insulin

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Ret also known as "rearranged during transfection" is a receptor tyrosine kinase with a mass of approximately 170-175 kDa. Scientists often study Ret because of its key role in cellular signaling pathways. It is primarily expressed in neural crest-derived cells and tissues including the kidneys and the enteric nervous system. Ret is also found in various other cell types throughout the body such as endocrine and hematopoietic tissues.
Biological function summary

The Ret protein facilitates several critical processes within the body. It functions as part of a complex with co-receptors called GFRα (GDNF family receptor alpha) which are required for binding ligands such as GDNF (glial cell line-derived neurotrophic factor). This binding activates downstream signaling pathways that influence cell growth differentiation and survival particularly within the nervous system. The proper functioning of Ret is essential for the development and maintenance of these cellular environments.

Pathways

Ret is an important component of the MAPK/ERK and PI3K/AKT signaling pathways. These pathways mediate various cellular responses including cell proliferation survival and apoptosis. The interactions of Ret with other proteins like SHC and GRB2 within these pathways create ripple effects that impact larger cellular networks. Through these pathways Ret connects with multiple proteins to modulate essential biological processes.

Ret's dysregulation is closely associated with multiple endocrine neoplasia type 2 (MEN2) and Hirschsprung's disease. These conditions arise due to mutations affecting Ret's signaling capabilities. In MEN2 Ret mutations lead to uncontrolled cell growth often resulting in medullary thyroid carcinoma. Hirschsprung's disease on the other hand involves a failure in neural crest cell migration leading to congenital gut motility issues. Researchers explore Ret's interactions with other proteins such as endothelin receptor B (EDNRB) to further understand these diseases.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com